



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : C12N 15/90, 15/55, 9/22, C07K 14/435, A01K 67/027, A61K 48/00</p>	<p>A1</p>	<p>(11) International Publication Number: <b>WO 99/07871</b> (43) International Publication Date: 18 February 1999 (18.02.99)</p>
<p>(21) International Application Number: PCT/NL98/00456 (22) International Filing Date: 11 August 1998 (11.08.98) (30) Priority Data: 08/909,786 12 August 1997 (12.08.97) US (71) Applicants (for all designated States except US): HET NED- ERLANDS KANKER INSTITUUT [NL/NL]; Plesmanlaan 121, NL-1066 CX Amsterdam (NL). INTROGENE B.V. [NL/NL]; Wassenaarseweg 172, NL-2333 AL Leiden (NL). (72) Inventors; and (75) Inventors/Applicants (for US only): VALERIO, Domenico [NL/NL]; Gerbrandylaan 12, NL-2314 EZ Leiden (NL). SCHOUTEN, Govert, Johan [NL/NL]; Da Costastraat 82, NL-2321 AR Lieden (NL). PLASTERK, Ronald, Hans, Anton [NL/NL]; Zwarteweg 5, NL-1405 AA Bussum (NL). VAN LUENEN, Hendricus, Gerhard, Adrianus, Maria [NL/NL]; Leerdamhof 143, NL-1108 BM Amsterdam (NL). (74) Agent: SMULDERS, Th., A., H., J.; Verenigde Octrooi- bureaux, Nieuwe Parklaan 97, NL-2587 BN The Hague (NL).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>
<p>(54) Title: VECTORS AND METHODS FOR PROVIDING CELLS WITH ADDITIONAL NUCLEIC ACID MATERIAL INTEGRATED IN THE GENOME OF SAID CELLS</p> <div data-bbox="422 1176 1169 1722"> <p>The diagram illustrates the process of integrating nucleic acid material into a host cell genome. It starts with two circular plasmids: a Tc1 plasmid containing <i>kan</i>, <i>tet</i>, and <i>cam</i> genes, and a <i>gpa-2</i> plasmid containing an <i>amp</i> gene. An arrow labeled "In vitro transposition" points to the step "electroporate into DS841 lambda lysogen". From this step, two arrows lead to the final selection steps: "selection on amp: efficiency of electroporation and DNA recovery" and "selection on amp + kan/tet: transposition events".</p> </div> <p>(57) Abstract</p> <p>The present invention provides novel elements for improving genetic engineering techniques for producing recombinant nucleic acid molecules and/or recombinant cells. The novel elements are capable of integrating desired nucleic acid material into other nucleic acid materials, specifically into the genome of a host cell. The novel elements are derived from or based on transposons, in particular from the Tc/Mariner superfamily. In particular the essential elements of Tc1 enabling excision and pasting of the desired nucleic acid material are provided, together with the relevant transposase activity in cis or in trans.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Title: Vectors and methods for providing cells with additional nucleic acid material integrated in the genome of said cells.

The present invention relates to the field of genetic engineering, in particular to the field of methods for making recombinant vectors containing nucleic acids of interest, methods for making recombinant cells, preferably  
5 expressing recombinant products, and/or production of nucleic acids of interest.

In a further embodiment the invention relates to transgenesis of animals, plants or other organisms of medical, scientific or economic interest. In yet another  
10 embodiment the invention relates to tools for mutagenesis as well as to tools and means for localization and/or identification of nucleic acid sequences of interest (such as genes) in the genome of a host.

Many ways of providing cells with additional nucleic  
15 acids are now known in the field. Many proteins have been expressed in many kinds of cells, ranging from prokaryotic bacteria and bacilli, via yeast and fungi to plant cells, insect cells and mammalian cells.

Often expression of proteins as discussed above has  
20 met with success, there are however, certain areas in the field of recombinant technology where, because of safety issues or technical problems, such as stability of the additional nucleic acid material introduced, success has not been easy to achieve. Also, in the application of  
25 genetic engineering where the product is not a protein, but for instance a nucleic acid of interest (such as DNA, RNA or an antisense construct), the same or similar problems have been encountered. It is in these areas particularly that the present invention finds its use.

30 One of the problems encountered in recombinant technology is that it is often desirable to have the

additional nucleic acid material, which is introduced into a host cell, integrate in the genome of said host cell. Once the additional nucleic acid material is integrated in the genome its stability is much less an issue. Moreover, the integrated material is replicated together with the genome and thus will be present in the offspring of the recombinant cell as well. Vectors which are capable of providing for integration of additional nucleic acid material into a host cell are known, but they do suffer from some drawbacks which will be discussed below.

The present invention now provides a way in which a wide variety of vectors can be altered to integrate the desired additional nucleic acid in the genome of the host cell.

This means that vectors which did not (efficiently) integrate the desired additional nucleic acid material in the genome of the host cell, can now be provided with said ability.

One of the drawbacks of the integrating vectors of the prior art is that they are often not capable of transducing a host cell efficiently. Techniques such as electroporation and the like are then necessary for achieving transduction.

In some areas such treatments of cells may be unwanted or impossible. One such an area is for instance gene therapy. In such cases vectors which can efficiently transduce host cells on their own, or which can be packaged into recombinant viral particles and so infect host cells are often employed.

However, many of these vectors are then incapable of (efficient) integration of the desired additional nucleic acid material in the genome of the host. The present invention thus offers the best of both worlds in that it enables to prepare vectors capable of efficiently transducing and efficiently integrating desired additional nucleic acid material in a host cell. The invention solves this problem in that the nucleic acid to be integrated into a host cell genome is provided within a functional

transposon. Exogenous DNA has been introduced into the genome of a host using a transposon, however since transposons were, until the present invention, thought to be rather species specific, the applicability of such a system was thought to be very limited. At best, it was shown that a transposon functional in one fruit fly could also be used to integrate DNA into the genome of another species of fruit fly (Loutheris et al., 1995). The present inventors have found that, at least for a certain class of transposons, it is possible to use these transposons across wide phylogenetic barriers, which allows for wide application of these transposons as integration means for DNA into a wide variety of host genomes.

The invention thus provides a vector for providing a cell of a certain genus with additional nucleic acid material integrated in its genome, whereby said vector comprises two transposase binding sites, whereby said transposase binding sites may be the same or different and are derived from a transposon found in another genus, each in close proximity to a cut site for said transposase, whereby said additional nucleic acid material is located between said two transposase binding sites. It is of course clear that it is highly preferred to be able to use transposons over even wider phylogenetic barriers. The present invention thus provides a transposon-based integration system with a wide applicability.

Clear advantages of this system are for instance that: using a transposon will often lead to a more efficient integration into the host cell genome; using a transposon gives complete control of the integrating sequence (the termini of the integrating element are known); in the embodiment where gene (or DNA) localization is desired it will be an advantage that a transposon can integrate anywhere in the genome (especially useful in so-called mutagenesis experiments aimed at gene function, or in "gene-trap" experiments directed at tracing genes of interesting expression patterns). For expression purposes

it may be desirable to develop transposons with a more specific integration site in the genome, or to develop methods of integration which lead to a more specific integration site.

5        Preferably, said transposase binding sites and said cut sites are based on the corresponding sites in transposons from the Tc1/mariner superfamily of transposons, more preferably they are based on Tc1-like transposons. A very useful set of transposon elements is  
10    the minimum set required by the Tc1 transposon i.e. comprising the terminal 26 basepairs of Tc1 and in close proximity the cut site (TA) for Tc1 transposase.

      An important advantage of the transposons according to the invention is that they are self-sufficient. All that is  
15    needed is a functional transposase binding site, a transposase cut site and transposase activity functional for those sites. Transposase activity needed should be as limited as possible. The preferred class of transposons only needs a single transposase. A reason for the species-  
20    specificity of transposons reported until to date may be that transposons have been used that require host proteins in order to be able to jump. The host proteins may then be responsible for the species-specificity of for instance the transposons of bacterial origin, or the P-element. The  
25    class provided with the present invention needs no host-elements and has modest cis-trans requirements. Therefore these transposons are far more suitable for integrating nucleic acids of interest into the genome of a wide variety of hosts.

30        In a preferred embodiment where elements based on Tc1 are used such a transposon binding site seems to be at least the 26 terminal basepairs. Probably not all of these basepairs are essential for the function of this binding site. Some (conservative) changes in such a binding site  
35    may therefore be allowed. It seems that sequences of around 100 bp are most efficient as transposase recognition sites.

For the invention, the transposase recognition sites must be functional for the corresponding transposase-activity, which transposase of course may also be modified, mutated, shortened or lengthened when compared with the original transposase, as long as it has relevant transposase-activity. The transposase-activity may be encoded on the same vector as the other transposon elements, even as part of the transposon together with the desired additional nucleic acid material (in cis), but it may very suitably be provided to the cell to be transduced by another vector according to the invention or by another vector (in trans).

When the transposase-activity is provided in trans and is preferably encoded by a sequence under control of an inducible and/or repressible promoter, "jumping" of the transposon can be switched on and off. Once integration into the host genome has taken place this may be very useful.

A vector for the purposes of this invention is any nucleic acid vehicle which is capable of carrying the desired additional nucleic acid material and preferably capable of transduction of host cells and/or replication.

The desired additional nucleic acid material may be encoding a protein and thus comprise a gene and regulatory elements for expression. Proteins to be expressed will depend on the purpose of the transduction. Many useful proteins for many applications have been identified as good candidates for recombinant expression. All these may be expressed using the present invention.

Also, the additional nucleic acid material (DNA) may be transcribed (once transduced) into RNA molecules blocking transcription or translation of host cell (or viral) nucleic acids. Such additional nucleic acid material may for instance be an antisense RNA molecule.

Use of the invention in the field of gene therapy is particularly advantageous, as will be clear from the above. Viral vectors often contemplated for gene therapy (such as

adenovirus, retrovirus or adenoassociated virus) which are not capable of efficiently integrating the desired nucleic acid material into the genome of the infected cell, may now be provided with such capability. Other vectors not based  
5 on a virus, but provided with a means to deliver them to a target cell population can of course also be advantageously provided with an integration system according to the invention. Particularly the use of liposomes or polymers as a targetting system is contemplated.

10 As stated, the present invention provides an efficient means by which a variety of vectors may be used to integrate exogenous nucleic acid material in the genome of a host cell. Because the exogenous nucleic acid material is integrated into the host cell's genome the progeny of the  
15 recombinant host cell produced will possess the same recombinant capabilities as their parent. Thus, when stemcells are produced according to the invention, this will lead to very efficient gene therapy regimes. The vectors (or the integration system) of the invention can of  
20 course also be used to produce transgenic animals, plants or other organisms of scientific, economic or medical interest. Useful applications for transgenesis are well known in the art.

Thus methods using the vectors according to the  
25 invention to transduce cells or animals, plants, etc. are also disclosed and part of the invention, as are cells, animals or plants, etc. obtainable by such methods. Use of the invention in mutagenesis studies and the like is another preferred embodiment, as discussed hereinbefore.  
30 The invention will now be explained in more detail using Tc1 as a non-limitative example.

#### Detailed description

35 Tc1 belongs to the Tc1/mariner superfamily of transposons found in nematodes, arthropods and chordates



(Henikoff 1992; Raddice et al. 1994; Robertson 1995; Plasterk 1995). Both vertical and horizontal transfer have contributed to the spread of these elements throughout the animal kingdom (Robertson 1993; Radice et al. 1994; Robertson and Lampe 1995). The widespread occurrence of the Tc1/mariner family of transposons can be taken as an indication for the absence of species-specific host factors which limit the transfer between different species. Therefore, Tc1/mariner elements are attractive candidates for the development of gene delivery vectors.

Tc1-like elements are close to 1.7 kb in length, have short inverted terminal repeats flanking a transposase gene and have the conserved sequence CAGT at their termini, flanked by TA representing the target site, which is duplicated upon integration (Van Luenen et al. 1994). The element-encoded proteins share a homologous catalytic domain with bacterial transposases and retroviral integrases (Doak et al. 1994). Tc1 from *C. elegans* is a 1612 bp long transposon which has 54 bp inverted repeats flanking a gene encoding a 343 amino acid transposase (Emmons et al. 1983; Rosenzweig et al. 1983; Vos et al. 1993), that binds to the inverted repeats (Vos et al. 1993; Vos and Plasterk 1994). The conserved hexanucleotide sequence, TACAGT (SEQ ID NO: -), at the extreme termini of the element is not part of the transposase binding site, but is thought to play a role in catalysis of the transposition reaction (Vos and Plasterk 1994).

Here, we describe in vitro excision and transposition of Tc1 using an extract prepared from transgenic nematodes. The minimal cis-requirements for transposition are defined and the target site choice in vitro is compared with that in vivo. Furthermore, we demonstrate that recombinant transposase purified from *E. coli* is capable of supporting transposition, showing that no other factors are essential for Tc1 transposition in vitro.

Moreover, we show that Tc1-transposase supports jumping of Tc1-derived transposons carrying a neomycin resistance gene into the genome of human cells. This demonstrates that it is possible to construct transposon-  
5 derived vectors that are capable of providing for integration of additional nucleic acid material into host cells across large phylogenetic barriers, which makes such vectors suitable as integrating gene delivery vehicles for a wide variety of host genomes, including that of humans.

10

## Results

### *Transposition of Tc1 in vitro*

We generated a transgenic worm with the Tc1 transposase gene under the control of a heat shock  
15 promoter. This allowed the preparation of a nuclear extract with elevated levels of transposase, which proved to be highly important to detect activity. The extract was incubated with a plasmid containing a Tc1 element. Excision was studied in a physical assay. Southern blot analysis of  
20 reaction products shows the appearance of excised Tc1 elements (fig. 1, lane 1).

Furthermore, cleavage at either the left or the right end of Tc1 is detected when the products are digested with Scal within the plasmid backbone prior to electrophoresis  
25 (lane 2). Cleavage may require a divalent cation ( $Mg^{2+}$  or  $Mn^{2+}$ ) and is stimulated by the presence of ethylene glycol or 5% DMSO (data not shown). The efficiency of cleavage at a single end of the transposon is not decreased if the substrate is linear (compare lanes 2 and 5). Also, deletion  
30 of either end of the transposon does not abolish cleavage at the remaining end (lanes 6 and 11), which suggests that cleavage does not require interaction between the two ends. In contrast to single end cleavage, excision of the complete element is reduced about 2-fold when the substrate  
35 is linear, suggesting that coordinated cutting at both ends is stimulated by supercoiling of the substrate. The

majority of complete excision products observed with a linear substrate can be explained by non-coordinated cleavages at both ends.

To determine the positions of the double strand cleavages at the nucleotide level, a PCR based primer extension was performed using end-labeled oligonucleotides specific for each strand (Fig. 2). The 5' cut is 2 bp within the transposon, whereas the 3' cut maps to the end of the transposon, as based on the largest observed PCR product. This confirms the model based on in vivo studies of the related *C. elegans* transposon Tc3, for which it was shown that excision results in a 2 bp staggered 3' overhang (Van Luenen et al. 1994). The complete excision of Tc1 shows that transposition occurs via a cut-and-paste process, a result consistent with genetic data on double strand break repair of the donor DNA molecule upon Tc1 excision (Plasterk 1991).

We devised a sensitive assay to detect integration events. We selected for jumping of a transposon-borne antibiotic resistance gene from a supercoiled donor plasmid to a target plasmid in a genetic assay (Fig. 3). Electroporation of reaction products into the appropriate *E. coli* strain resulted in the detection of many transposition events (Table 1). Extracts prepared from non-transgenic N2 worms or from the so-called high-hopper strain, TR679 (Collins et al. 1987), which has a high frequency of germline transposition, do not generate a detectable level of transposition products in this assay. Linearization of the donor plasmid resulted in an approximately 20-fold reduced efficiency of transposition. Transposition requires two inverted repeat sequences, because no integrations were obtained upon deletion of one transposon end. Furthermore, the addition of ATP, GTP or dNTPs does not increase the level of transposition (data not shown), which indicates that the process is neutral in energy-consumption and independent of a cofactor. About 90

independent in vitro Tc1 integrations were analyzed by sequencing and found at TA dinucleotides, which had been duplicated in the process. Two odd integration events were detected, where Tc1 had integrated in the sequence TTG (SEQ ID NO: -) or CCT (SEQ ID NO: -). In both cases, we found a 3 bp target site duplication.

#### *Target site choice*

Previously, several hundreds of in vivo Tc1 and Tc3 integrations in a 1 kb region of the *gpa-2* gene have been analyzed (Van Luenen and Plasterk 1994). This showed the selective use of a limited set of TA dinucleotides as targets of integration, with a striking difference in preference between Tc1 and Tc3. To investigate whether the chromatin structure played a role in the choice of integration sites, we determined the pattern of integrations into naked DNA in vitro, using the same target region previously assayed in vivo. Therefore, we included the *gpa-2* region in our target plasmid. It is apparent that the same overall pattern of integration is seen (Fig. 4). Hot sites in vivo appear to be hot in vitro and cold sites in vitro are also cold in vivo. This indicates that, at least in this region of the genome, the genome, the chromatin structure or the transcriptional status of the DNA in vivo is not the major determinant of target choice.

#### *Transposition by recombinant transposase*

The nematode is not a convenient source of protein for an extensive purification of transposase. Therefore, we expressed the protein in a heterologous system. Both expression using Baculovirus and Sf9 cells (data not shown) or expression in *E. coli* yielded transposase capable of supporting Tc1 transposition. Recombinant transposase was purified from inclusion bodies to near homogeneity (Fig. 5). Table 1 shows the frequency of transposition when comparable amounts of transposase were used for both the

worm extract and the purified protein. Sequence analysis of 9 independent integrations in case of the recombinant protein showed that transposition into TA target sequences that were duplicated, from which it can be concluded that

5 *bona fide* transposition had occurred. Therefore, we conclude that Tc1 transposase is the only protein required for Tc1 transposition. The difference in efficiency between nematode derived and bacterial transposase needs further studies. It could reflect a folding problem of the

10 bacterial transposase, which was denatured and refolded during the purification procedure, or the stimulatory role of host factors present in the nematode extract.

#### *Minimal cis-requirements*

15 We investigated the possibility that the terminal 26 bp of Tc1 which constitute a full transposase binding site, flanked by the TA target site, are sufficient to form an artificial transposon. An element consisting of only these Tc1-specific sequences is still able to transpose in vitro,

20 albeit at a lower frequency (Table 1). We sequenced several integrations and found them to be correct.

Furthermore, we investigated the importance of the conserved hexanucleotide sequence TACAGT (SEQ ID NO.: -). Mutations were introduced at one of the ends of a mini-Tc1

25 which contains only the terminal 26 bp as well as the flanking TA dinucleotide. Whereas excision of the element with 2 wild-type ends is easily detected in a physical assay, mutation of the transposase binding site, the flanking TA sequence of the termini, resulted in the

30 inability of the element to excise (Fig. 6). Double strand cleavage at the wild-type end was not affected by mutation at the other transposon end. Analysis of cleavage by PCR based primer extension revealed that, for the CA to TG mutation only, single stranded breaks at the 5' end of the

35 transposon had occurred (data not shown).

We have developed a cell-free Tc1 transposition system. Excision occurs by double strand breaks at the transposon ends resulting in 2 bp staggered 3' overhangs. A cut-and-paste mechanism of transposition appears to apply for Tc1 (Fig. 7). This mechanism was already proposed on the basis of genetic data (Plasterk 1991) as well as the analysis of in vivo transposition products (Van Luenen et al. 1994). Nonreplicative transposition is shared with the bacterial transposons Tn7 (Bainton et al. 1991, 1993) and Tn10 (Bender and Kleckner 1986) as well as the *Drosophila* P element (Kaufman and Rio 1992). In contrast, the Mu and Tn3 transposable elements transpose via a replicative mechanism (Grindley and Sherratt 1978; Shapiro 1979; Mizuuchi 1992). Tc1 transposition appears to be independent of addition of a nucleotide cofactor, whereas P elements use GTP (Kaufman and Rio 1992) and Tn7 uses ATP as cofactor (Bainton et al. 1993).

A striking feature of the Tc1/mariner family is the use of a TA dinucleotide as target site. An extensive study of target site choice in vivo had revealed the usage of only a subset of the available TA dinucleotides and a marked difference in target choice between the two related transposons Tc1 and Tc3 in *C elegans* (Van Luenen and Plasterk 1994). We find the same overall integration pattern in vitro as had been observed in vivo. This suggests that the chromosomal context of the DNA does not affect target choice, at least in the region of the genome analyzed. Therefore, we favor the idea that the transposition complex primarily selects its target site on the basis of the primary DNA sequence flanking the TA, although a strong consensus sequence could not be identified (Van Luenen and Plasterk 1994). A clear influence of the chromatin structure has been demonstrated for retroviral integrations (Pryciak and Varmus 1992; Müller and Varmus 1994). These studies showed a preference for regions within nucleosomal DNA, probably due to the

bending of the DNA. We cannot exclude that DNA binding proteins can affect regional preferences for Tc1 integration. Because nothing is known about the chromosomal organization of the *gpa-2* gene, it will be of interest to  
5 compare integration sites using reconstituted nucleosomal DNA in vitro.

Transposition in vitro requires the extreme termini of the transposon containing the transposase binding site and the conserved hexanucleotide sequence, which is important  
10 for excision. We observe a decrease in transposition efficiency between transposition of a full-length transposon and the Tc1 element with only 26 bp terminal inverted repeats, which suggests that additional sequences can contribute to transposition efficiency. We have no  
15 indications for additional transposase binding sites, but perhaps small basic proteins like high mobility group proteins (Grosschedl et al. 1994) may bind and stimulate transposition. Alternatively, unique A-T-rich sequences found at the transposon ends may add a helping bend to the  
20 DNA. The conserved hexanucleotide sequence at the extreme termini of the transposon are shown to be important at least for the cleavage step. The 5' end single strand cleavage seen for one of the mutations (CA to TG) is perhaps an indication for a specific order of single strand  
25 cleavages, i.e. first the non-transferred strand, which would be the opposite of what has been reported for Tc10 (Bolland and Kleckner 1995).

Transposase purified from *E. coli* to near homogeneity is able to execute jumping of Tc1, which indicates that  
30 transposase is the only protein required for excision and integration of Tc1. The higher efficiency obtained with the nematode extract suggests that host factors may enhance the frequency of the reaction. It has for instance been shown that the mammalian proteins HMG1 and HMG2 can stimulate  
35 prokaryotic recombinations (Paull et al. 1993). The independence of species-specific factors might be the

explanation why members of the Tc1/*mariner* family are dispersed over so many different phyla, possibly by means of horizontal transfer (Robertson and Lampe 1995). This is in contrast to P elements which are restricted to

5 *Drosophila* species. Transposition of P elements in other species has not been observed (Rio et al. 1988). A possible candidate for a species-specific host factor in P transposition is the inverted repeat binding protein, IRBP (Beall et al. 1994). The simple cis- and trans-

10 requirements for Tc1 transposition in vitro shows that this transposable element will be a good vector for gene delivery in a wide variety of animals. In order to determine the feasibility of the use of Tc1 transposons in human cells, we first tested whether the Tc1-transposase is

15 toxic for human cells. The Tc1-transposase expression vector pRc/CMV.Tc1A or the empty vector pRc/CMV (Invitrogen) was transfected into 911 cells, a human embryo retina cell line transformed by early region I of adenovirus type 5. Approximately 48 hours post-

20 transfection, the cells were put on G418 selection medium. Stable cell lines derived from single colonies were established and screened for Tc1-transposase protein on a western blot (figure 8). All pRc/CMV.Tc1A transfected cell lines expressed Tc1-transposase, demonstrating that

25 expression of Tc1-transposase is not toxic for human cells.

Next, we examined whether Tc1-transposase supports transposition of a Tc1-derived transposon in human cells. To that end, the plasmid pRP466.SV-neo1.PGK-tk2 was constructed. This plasmid contains a neomycin resistance

30 gene expression cassette under control of the SV40 promoter (SV-neo) flanked by the inverted repeats of Tc1 and an expression cassette for the Herpes Simplex Virus thymidin kinase under control of the phospho-glyceraldehyde kinase promoter (PGK-tk) outside of the Tc1 inverted repeats.

35 Excision of the SV-neo transposon from pRP466.SV-neo1.PGK-tk2 was tested in an *in vitro* excision assay using



transposase purified from *E.coli*. Southern blot analysis of the reaction products shows the appearance of excised 2.9 kb Tc1.SV-neo elements (figure 9). Thus, pRP466.SV-neo1.PGK-tk2 can serve as a Tc1.SV-neo transposon donor plasmid.

To determine whether transposition of Tc1 transposon-derived vectors occurs in human cells, the cell line 911 was transfected with the plasmid pRP466.SV-neo1.PGK-tk2, together with the Tc1-transposase expression vector pcDNA1/Tc1A or with the empty vector pcDNA1/amp (Invitrogen). Forty eight hours post-transfection, the cells were put on G418 selection. After 18 days, G418 resistant colonies were counted (table 2). Co-transfection of pcDNA1/Tc1A yielded approximately 40% more G418 resistant colonies, suggesting that , in addition to random integration, G418 resistant colonies were formed due to jumping of the Tc1-neo transposon into the cellular genome.

The presence of the PGK-tk expression cassette on the plasmid pRP466.SV-neo1.PGK-tk2 outside of the Tc1 inverted repeats allowed us to discriminate between plasmid integration and transposition of the Tc1.SV-neo transposon. Thymidin kinase phosphorylates the anti-viral prodrug Ganciclovir (GCV), after which it acts as a chain terminator of DNA synthesis, thereby killing the tk expressing cells. When plasmid integration occurs, in most cases both the SV-neo and PGK-tk expression cassettes are integrated into the 911 genome, rendering the cell lines G418 resistant and GCV sensitive. When transposition of the SV-neo transposon takes place, however, the cell lines will be G418 resistant and GCV insensitive, because the PGK-tk expression cassette is not integrated into the host cell genome. In total, 73 independent G418 resistant cell lines were established from the above mentioned transfection, and screened for to GCV. Table 3 shows that co-transfection of pRP466.SV-neo1.PGK-tk2 with pcDNA1/Tc1A resulted in the

formation of more tk-negative cell lines (64-77%) than co-transfection with pcDNA1/amp (32-44%).

Random integration of circular plasmid DNA first requires linearization of the DNA due to a double strand DNA break before integration into the host genome can occur. The PGK-tk expression cassette covers approximately 1/3 of the total of the plasmid DNA (excluding the neomycin SV-neo expression cassette for which the cell lines were selected). If this process is assumed random and if a single copy of the plasmid integrates, one would expect around 33% of the DNA breaks to occur in the PGK-tk expression cassette, thereby abolishing tk expression. Therefore, the percentage tk negative cell lines that were generated by co-transfection of pRP466.SV-neo1.PGK-tk2 and pcDNA1/amp was within expectation. The higher incidence of GCV resistant clones after co-transfection of pRP466.SV-neo1.PGK-TK2 with pcDNA1/TclA again strongly suggests that the Tcl.SV-neo transposon jumped from the pRP466.SV-neo1.PGK-TK2 into the human genome.

The most direct way to discriminate between plasmid integration- and transposition events is sequencing the DNA that flanks the transposon that is integrated into the host cell genome. After plasmid integration, the surrounding DNA sequences will be identical to the sequences flanking the transposon in the plasmid pRP466.SV-neo1.PGK-tk2. After transposition, the surrounding sequences will be of human genomic origin, and thus be different from those in the plasmid pRP466.SV-neo1.PGK-tk2. Genomic DNA from independent tk-minus/G418-resistant colonies was isolated and digested with Sau3A. To the genomic fragments, an oligo-cassette ("vectorette") was ligated. The vectorette consists of two oligonucleotides which have complementary sequences at their ends but are not complementary in the middle. Fragments that contain transposon and flanking sequences are amplified in a PCR using an oligo complementary to the transposon end and pointing to the flanking sequence in combination with an oligo that is

complementary to middle of the vectorette sequence. PCR products were analysed on an agarose gel and the amplified DNA fragments were sequenced. Thus far, in two out of five cases we found that the transposon was present, flanked by a TA dinucleotide and followed by a new sequence. These integrations represent genuine transposition events showing that Tc1 can jump in human cells when Tc1-transposase is provided.

## 10 Materials and methods

### *Plasmid constructions*

pRP466 contains a Tc1 element with 0.4 kb flanking sequences derived from pLM40 (Mori 1988) cloned as a *Bam*HI-*Xba*I fragment into pUC19, pRP467 and pRP468 are derivatives of pRP466 in which either a *Cla*I-*Asp*718 or *Pst*I-*Apa*I fragment is deleted. pRP472 is a pACB104 (Boyd and Sherratt 1995) derivative which contains Tc1 with the *Ava*I-*Hind*III fragment of pBR322 inserted between the *Cla*I and *Apa*I sites. Cloning of the *Xba*I-*Bam*HI fragment of pRP466 with the *Hind*II Kan<sup>R</sup>-cassette of pUC4K (Pharmacia) between the *Xho*I-sites into pACB104 resulted in pRP490. pRP491 is comparable to pRP490; all the internal Tc1 sequences have been replaced except the terminal 26 bp.

The plasmid pRP466.SV-neo1.PGK-tk2 was constructed as follows: pRP466 was digested with *Xho*I and blunted with Klenow and dNTPs. The plasmid pRc/CMV (Invitrogen) was digested with *Bam*HI and *Eco*RI and blunted with Klenow and dNTPs. Subsequently, the *Bam*HI/*Eco*RI SV-neo fragment was cloned into *Xho*I digested pRP466, giving rise to pRP466.SV-neo1. The plasmid pRP466.SV-neo1 was digested with *Eco*RI and blunted with Klenow and dNTPs. The plasmid pPGK-tk (PCT/NL/00195) was digested with *Pvu*II. The *Pvu*II PGK-tk fragment was cloned into *Eco*RI digested pRP466.SV-neo1, giving rise to pRP466.SV-neo1.PGK-tk2.

The plasmid pRc/CMV.TclA contains the Tcl-transposase cDNA, which was amplified from pRP470 (Vos et al., 1993) with the primers

5'CCCCAAGCTTGCCACCATGGTAAAATCTGTTGGGTGTAAAAATC (SEQ ID NO.: -) and 5'GCTCTAGATGCTTAATACTTTGTCGCGTATCC (SEQ ID NO.: -) using eLONGase according to standard protocol of the supplier (Gibco BRL). PCR was performed on a Biometra Trio Thermoblock, Amplification program: 94°C for 1 minute, 1 cycle; 94 °C for 30 seconds + -52 °C for 30 seconds + 68 °C for 1 minute , 35 cycles; 68 °C for 1 minute. The PCR fragment was digested with *HindIII*/*XbaI* and cloned into *HindIII*/*XbaI* digested pRc/CMV, giving rise to pRc/CMV.TclA. The integrity of the TclA cDNA was confirmed by sequencing. The pRc/CMV plasmid contains a neomycin resistance gene expression cassette. The plasmid pcDNA1/TclA contains the *HindIII*/*XbaI* TclA fragment of pRc/CMV.TclA cloned into *HindIII*/*XbaI* digested pcDNA1/amp (Invitrogen). The pcDNA1/amp plasmid does not contain a neomycin resistance gene expression cassette. All restriction enzymes, primers, Klenow and dNTPs were purchased from Gibco BRL.

#### Southern blotting

For figure 9: The product of the *in vitro* excision reaction was separated on a 0.8% agarose 0.5 x TBE gel by electrophoresis for 5 hours at 70 Volts. Subsequently the gel was rinsed in Southern blot buffer (0.4 M NaOH, 0.6 M NaCl) for 30 minutes and the DNA was blotted overnight onto Hybond-N<sup>+</sup> (Amersham). After blotting, the gel was rinsed in 5xSSPE and pre-hybridised for 3 hours in 50% formamide, 5xDenhardts, 5xSSPE, 5% dextrane sulphate, 1% SDS and 200 µg/ml haring sperm DNA and overnight hybridised with a randomly primed <sup>32</sup>P-labelled (RTS radprime DNA labeling system, Gibco BRL) neo probe (*NcoI* fragment of pPGK-tk) at 42°C. Subsequently the blot was extensively washed in

5xSSPE/0.1% SDS at 65°C. The blot was exposed to HyperFilm (Amersham) at room temperature.

#### *Western blotting*

5 Cells were washed twice with PBS (NPBI) and lysed and scraped in RIPA (1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS in PBS, supplemented with 1mM phenylmethylsulfonylfluoride and 0.1 mg/ml trypsin inhibitor). After 15 minutes incubation on ice, the lysates  
10 were cleared by centrifugation. Protein concentrations were determined by the Bio-Rad protein assay, according to standard procedures of the supplier (BioRad). Whole-cell extracts were fractionated by SDS-PAGE on 10% gels. Proteins were transferred onto Immobilon-P membranes  
15 (Millipore) and incubated with an  $\alpha$ Tcl transposase antibody (Schukkink et al., 1990). The secondary antibody is a horseradish-peroxidase conjugated goat anti rabbit antibody (BioRad). The antibody complexes were visualized with the ECL detection system according to the manufacturer's  
20 protocol (Amersham).

#### *Cell culture and Transfection*

The cell line 911 (Fallaux et al., 1996) was cultured in Dulbecco's modified Eagles medium (Gibco BRL)  
25 supplemented with 10% FBS (Gibco BRL) at 37°C and 5% CO<sub>2</sub>. Selection of the transfected cells with G418 (Gibco BRL) was performed at a concentration of 500 µg/ml. Selection with Ganciclovir (Roche) was performed at a concentration of 10 µg/ml. DNA was transfected into 911 cells using the  
30 Calcium Phosphate Transfection System, according to the manufacturer's protocol (Gibco BRL). Briefly, 1 day prior to transfection, 911 cells were plated at 30% density on 5 cm tissue culture dishes (Greiner). The next day, cells were incubated with calcium phosphate precipitated DNA for  
35 15 hours. Subsequently, the cells were washed twice with PBS and fresh medium was added. Approximately 48 hours post-

transfection cells were put on G418 selection medium. G418 resistant colonies appeared around day 6. Single colonies were picked and cell lines were established.

#### 5 Sequencing of the transposon flanks

100 ng genomic DNA was digested in 20 µl using 4 units *Sau3A* (Boehringer Mannheim) according to instructions of the supplier. After 2 hours at 37°C the enzyme was inactivated by incubating 15 minutes at 65°C. Equimolar amounts of the vectorette oligo's (503:  
5'GATCCAAGGAGAGGACGCTGTCTGTCTGAAGGTAAGGAACGGACGAGAGAAGGGAGA  
and 504  
5'TCTCCCTTCTCGAATCGTAACCGTTTCGTACGAGAATCGCTGTCCTCTCCTTG)  
were mixed in the presence of 10 mM Tris-HCl pH7.5 and 1mM  
EDTA. The mixture was heated to 80°C and allowed to cool  
down to 40°C. The final concentration of the vectorette-  
oligo-cassette is 10 pmol/µl. 15 pmoles of the vectorette  
were overnight ligated at 16°C to the digested DNA in a 100  
µl volume using 5 units ligase (Boehringer Mannheim)  
according to the instructions of the supplier. In the first  
PCR, 3 µl of the DNA is used in a volume of 25 µl using 1  
unit Taq polymerase (Gibco BRL) according to the  
instructions of the supplier. The final concentration of  
the oligo's is 0.4 pmoles. The PCR consisted of 30 cycles  
with 1 minute at 95°C, 1 minute at 58°C and 1 minute at  
72°C. To increase the specificity and the sensitivity a  
second PCR with nested primers was performed using 0.01 µl  
template from the first PCR. The conditions of the PCR were  
identical to the first PCR. The oligo's used are Tc1L2 (5'-  
TCAAGTCAAATGGATGCTTGAG) (SEQ ID NO:5) or Tc1R2  
(5'- GATTTTGTGAACACTGTGGTGAAG) (SEQ ID NO:6) and 337new  
(5'-GTACGAGAATCGCTGTCCTC) (SEQ ID NO:7). The PCR products  
were analysed on a 1 % agarose gel. Amplified DNA fragments  
were excised from gel and DNA was extracted using the QIAEX  
II gel extraction kit (Qiagen). The DNA was taken up in 20  
µl water after isolation from gel. The transposon primer

Tc1L2 or Tc1R2 was radiolabeled using  $^{32}\text{P}$ -ATP and polynucleotide kinase (Boehringer Mannheim) according to the instructions of the supplier. Using 0.25 pmoles of radiolabeled primer and the isolated DNA a PCR was  
5 performed using 0.5 units Taq polymerase (Gibco BRL) and one of the ddNTP mixtures (containing either ddATP (160  $\mu\text{M}$  ddATP and 5  $\mu\text{M}$  of each dNTP in 10 mM Tris-HCl pH 8, 1 mM EDTA), ddTTP (250  $\mu\text{M}$  ddTTP and 5  $\mu\text{M}$  of each dNTP in 10 mM Tris-HCl pH 8, 1 mM EDTA), ddGTP (32  $\mu\text{M}$  ddGTP and 5  $\mu\text{M}$  of  
10 each dNTP in 10 mM Tris-HCl pH 8, 1 mM EDTA) or ddCTP (160  $\mu\text{M}$  ddCTP and 5  $\mu\text{M}$  of each dNTP in 10 mM Tris-HCl pH 8, 1 mM EDTA)). The final volume was 20  $\mu\text{l}$ . 20 cycles were performed with 1 minute at 95°C; 1 minute 58°C; 1 minute 72°C. The samples were analysed on a 6 % denaturing  
15 polyacrylamide gel in 1 x TBE.

#### *Transgenesis of C. elegans*

A transgenic Bristol line was obtained after microinjection (Mello et al. 1991) of 150 mg/ml pRP469 and  
20 5 mg/ml pRP465 (Vos et al. 1993), 50 mg/ml pRF4 (Kramer et al. 1990) in strain CB1392 (nuc-1 9e1392)). A stable line, NL818(pk1s221), was generated by X-ray irradiation (Way et al. 1991).

#### 25 *Extract preparation*

Stable line NL818 was grown in liquid culture at 18°C and heat shocked for 3 hours at 33°C to induce transposase expression. After 2 hours of further growth at 18°C, nuclear extracts were prepared as described (Vos et al.  
30 1993) with differences in the buffers. NIB: 25 mM Tris pH 7.5, 20 mM KCl, 0.5 M sucrose, 0.5 mM EDTA, 5 mM b-mercaptoethanol, 0.1 mM PMSF, NEB: 25 mM Tris pH 7.5, 0.1 mM EDTA, 500 mM NaCl, 15% glycerol, 0.25% Tween-20, 0.1 mM PMSF, 1 mM DTT. Nuclear extract contains 2.5 mg/ml protein;  
35 concentration of Tc1A is about 10 mg/ml.

*Recombinant transposase expression and purification*

*E. coli* strain BL21 pLySS was transformed with pRP470 containing the Tc1 transposase gene under the control of a T7 promoter (Vos et al. 1993), grown in 2xYT medium and induced at an OD of 0.6 at 600 nm with 0.5 mM IPTG for 3 hours at 37°C. Inclusion bodies were purified as described by Nagai and Thogersen (1978). Inclusion bodies were dissolved in 8 M urea, 20 mM Na-phosphate pH 6.0 and loaded on a CM cellulose CL-6B column (Pharmacia). The protein was eluted with a linear gradient from 0 to 500 mM NaCl. The transposase containing fraction was loaded on a Sephacryl S400 HR gel filtration column equilibrated in 6 M guanidiniumhydrochloride, 50 mM Tris pH 8.0. Transposase fractions were dialysed against 8 M urea, 50 mM Tris pH 8.0, 1 mM DTT. The protein was loaded on a S Sepharose FF column and eluted with 500 mM NaCl in the same buffer. All steps were performed at room temperature. The protein was renatured by a 100x dilution into ice-cold buffer: 50 mM Tris pH 8.0, 100 mM NaCl, 5 mM DTT, 5 mM MgCl<sub>2</sub>. After 30 minutes, insoluble protein was removed by centrifugation for 15 minutes in an Eppendorf centrifuge. Transposase concentration was 200 mg/ml and estimated to be more than 90% pure.

*In vitro transposition reactions*

Standard reaction conditions: 25 mM Tris pH 8.0, 25 mM NaCl, 1 mM DTT, 10% ethylene glycol, 5 mM MgCl<sub>2</sub> (or 2.5 mM EDTA), 4 mM spermidine, 0.05 mg/ml BSA. 200 ng of donor plasmid was preincubated with 2.5 ml worm extract or 0.25 ml of purified protein for 5 minutes on ice before addition of 2.5 µg target DNA in a total volume of 50 µl. Incubation was for 1 hour at 30°C. Reactions were stopped by addition of 5.5 µl of 250 mM Tris pH 8.0, 50 mM EDTA, 5% SDS, 2 mg/ml proteinase K. After 1 hour at 37°C, the DNA was precipitated and resuspended in 50 µl water.



*Mapping of in vitro cleavage sites*

Linear PCR amplicification was in 20 ml using 5 ml template and 0.5 pmol primer for 20 cycles; 1' at 94°C, 1' at 60°C, 1' at 72°C, essentially as described (Craxton 1991). Sequence primers: B1GR =  
5'AGATTTCCCACTTATATCATGTTTTATGTTTTGC (SEQ ID NO:8) , R2 (Van Luenen and Plasterk 1994).

*Genetic assay*

10 Electrocompetent DS941 lambda lysogen (Flinn et al. 1989) bacteria were prepared and used as described (Zabarovsky and Winberg 1990). The donor plasmid contains a lambda origin of replication and can not replicate in the DS941 lambda lysogen; the target plasmid has Col E1 origin  
15 of replication. One to 5 ml of DNA was used per electrophoration and 5% of the bacteria were, after dilution, plated on ampicillin. The remaining bacteria were plated on double selection. This yielded, depending on the efficiency upto 200 transformants.

### References

- Bainton, R.J., P. Gamas, and N.L. Craig, 1991. Tn7 transposition in vitro proceeds through an excised transposon intermediate generated by staggered breaks in DdNA. *Cell* 65: 805-816.
- 5 Bainton, R.J., K.M. Kubo, J.-n. Feng, and N.L. Craig, 1993. Tn7 transposition: target DNA recognition is mediated by multiple Tn7-encoded proteins in a purified in vitro system. *Cell* 72: 931-943.
- Beall, E.L., A. Admon, and D.C. Rio, 1994. A *Drosophila* protein homologous to the human p70 Ku autoimmune antigen  
10 interacts with the P transposable element inverted repeats. *Proc.Natl.Acad.Sci. USA* 91: 12681-12685.
- Bender, J. and N. Kleckner, 1986. Genetic evidence that Tn10 transposes by a nonreplicative mechanism. *Cell* 45:  
15 801-815.
- Bolland, S. and N. Kleckner, 1995. The two single-strand cleavages at each end of Tn10 occur in a specific order during transposition. *Proc.Natl.Acad.Sci. USA* 92: 7814-7818.
- 20 Boyd, A./C. and D.J. Sherratt, 1995. The pCLIP plasmids: versatile cloning vectors based on the bacteriophage lambda origin of replication. *Gene* 153: 57-62.
- Clar, J.M. 1988. Novel non-templated nucleotide addition  
25 catalyzed by procaryotic and eukaryotic DNA polymerases. *Nucleic Acids Res.* 16: 9677-9686.
- Collins, J., B. Saari, and P. Anderson, 1987. Activation of a transposable element in the germ line but not the soma of *Caenorhabditis elegans*. *Nature* 328: 726-728.
- 30 Craxton, M, 1991. Linear amplification sequencing, a powerful method for sequencing DNA. *METHODS: A companion to Meth. Enzymol.* 3: 20-26.

- Doak, T.G., F.P. Doerder, C.L. Jahn, and G. Herrick, 1994. A proposed superfamily of transposase-related genes: new members in transposon-like elements of ciliated protzoa and a common "D35E" motif. *Proc.Natl.Acad.Sci. USA* 91: 942-946.
- 5 Emmons, S.W., L. Yesner, K.-s. Ruan, and D. Katzenberg, 1983. Evidence for a transposon in *Caenorhabditis elegans*. *Cell* 32: 55-65.
- Fallaux, F.J., Kranenburg, O., Cramer, S.J., Houweling, A., van Ormondt, H., Hoebe, R.C. and van der Eb, A.J. 1996.
- 10 Characterization of 911: A new helper cell line for the titration and propagation of early region-1 deleted adenoviral vectors. *Human Gene Therapy* 7: 215-222.
- Flinn, H.L., M. Burke, C.J. Stirling, and D.J. Sherratt, 1989. Use of gene replacement to construct *Escherichia coli*
- 15 strains carrying mutations in 2 genes required for stability of multicopy plasmids. *J.Bacteriol.* 171: 2241-2243.
- Grindley, N.D.F. and D.J. Sherratt, 1978. Sequence analysis of IS1 insertion sites: models for transposition. *Cold*
- 20 *Spring Harbor Symp. Quant. Biol.* 45: 125-133.
- Grosschedl, R., K. Giese, and J. Pagel, 1994. HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. *Trends Genet.* 10: 94-100.
- Henikoff, S, 1992. Detection of *Caenorhabditis* transposon
- 25 homologs in diverse organism. *New Biol.* 4: 382-388.
- Kaufman, P.D., and D.C. Rio, 1992. P element transposition in vitro proceeds by a cut-and-paste mechanism and uses GTP as cofactor. *Cell* 69: 27-39.
- Kramer, J.M., R.P. French, E. Park, and J.J. Johnson, 1990.
- 30 The *Caenorhabditis elegans* *rol-6* gene, which interacts with the *sqt-1* collagen gene to determine organismal morphology encodes a collagen. *Moll.Cel. Biol.* 10: 2081-2089.
- Loukeris, T.G., Livadaras, I., Arca, B., Zabalou, S., Savakis, C., 1995. Gene transfer into the medfly, *Ceratitis*

- capitata, with a *Drosophila hydei* transposable element.  
*Science*, 270(5244): 2002-5
- Mello, C.C., J.M. Kramer, D. Stinchcomb, and V. Ambros,  
1991. Efficient gene transfer in *C. elegans*:  
5 extrachromosomal maintenance and integration of  
transforming sequences. *EMBO J.* 10: 3959-3970.
- Mizuuchi, K. 1992. Transpositional recombination:  
mechanistic insights from studies of Mu and other elements.  
*Annu. Rev. Biochem.* 61: 1011-1051.
- 10 Mori, I. 1988. "Analysis of germline transposition and  
excision of Tc1 transposable elements in *Caenorhabditis*  
*elegans*". Ph. D. thesis. Washington University, St. Louis,  
MO.
- Müller, H.-P. and H.E. Varmus, 1994. DNA bending create  
15 favored sites for retroviral integration: an explanation  
for preferred insertion sites in nucleosomes. *EMBO J.* 13:  
4704-4714.
- Nagai, K. and H.C. Thogersen, 1987. Synthesis and sequence-  
specific proteolysis of hybrid proteins produced in  
20 *Escherichia coli*. *Methods Enzymol.* 153: 461-481.
- Paull, T.T., M.J. Haykinson, and R.C. Johnson, 1993. The  
nonspecific DNA-binding and -bending proteins HMG1 and HMG2  
promote the assembly of complex nucleoprotein structures.  
*Genes & Dev.* 7: 1521-1534.
- 25 Plasterk, R.H.A. 1991. The origin of footprints of the Tc1  
transposon of *Caenorhabditis elegans*, *EMBO J.* 10: 1919-  
1925.
- Plasterk, R.H.A., 1995. The Tc1/*mariner* transposon family.  
In *Transposable Elements* (eds. H. Seadler and A. Gierl),  
30 Springer Verlag, Heidelberg.
- Pryciak, P.M. and H.E. Varmus, 1992. Nucleosomes, DNA-  
binding proteins, and DNA sequence modulate retroviral  
integration target site selection. *Cell* 69: 769-780.
- Radice, A.D., B. Bugaj, D.H.A. Fitch, and S.W. Emmons,  
35 1994. Widespread occurrence of the Tc1 transposon family:

- Tc1-like transposons from teleost fish. *Mol. Gen. Genet.* 244: 606-612.
- Rio, D.C., G. Barnes, F.A. Laski, J. Rine, and G.M. Rubin, 1988. Evidence for *Drosophila* P element transposase activity in mamalian cells and yeast. *J. Mol. Biol.* 200: 411-415.
- Robertson, H.M. 1995. The Tc1-mariner superfamily of transposons in animals. *J. Insect. Physiol.* 41: 99-105.
- Robertson, H.M. 1993. The mariner transposable element is widespread in insects. *Nature* 362: 241-245.
- Robertson, H.M. and D.J. Lmape, 1995. Recent horizontal transfer of a mariner transposable element among and between Diptera and Neuroptera. *Mol. Biol. Evol.* 12: 850-862.
- Rosenzweig, B., L.W. Liao, and D. Hirsch, 1983. Sequence of the *C. elegans* transposable element Tc1. *Nucleic Acids Res.* 12: 4201-4209.
- Schukkink, R.F. and Plasterk, R.H.A. 1990. TcA, the putative transposase of the *C. elegans* Tc1 transposon, has an N-terminal DNA binding domain. *Nucleic Acids Research* 18: 895-900.
- Shapiro, J.A, 1979. Molecular model for the transposition and replication of bacteriophage Mu and other transposable elements. *Proc. Natl. Acad. Sci. USA* 76: 1933-1937.
- Van Luenen, H.G.A.M. and R.H.A. Plasterk, 1994. Target site choice of the related transposable elements Tc1 and Tc3 of *Caenorhabditis elegans*. *Nucleic Acids Res.* 22: 262-269.
- Van Luenen, H.G.A.M. van Luenen, and R.H.A. Plasterk, 1993. Characterization of the *Caenorhabditis elegans* Tc1 transposase in vivo and in vitro. *Genes & Dev.* 7: 1244-1253.
- Vos, J.C. and R.H.A. Plasterk, 1994. Tc1 transposase of *Caenorhabditis elegans* is an endonuclease with a bipartite DNA binding domain. *EMBO J.* 13: 6125-6132.

- Way, J.C., L. Wang, J.-O. Run, and A. Wang, 1991. The *mec-3* gene contains cis-acting elements mediating positive and negative regulation in cells produced by asymmetric cell division in *Caenorhabditis elegans*. *Genes & Dev.* 5: 2199-2211.
- 5 Zabarnosky, E.R. and G. Winberg, 1990. High efficiency electrophoration of ligated DNA into bacteria. *Nucleic Acids Res.* 18: 5912.

**Legend**

**Figure 1.** Southern blot analysis of in vitro Tc1 transposition reaction products. Products of in vitro transposition reactions were separated on a 1% agarose gel, transferred to nitrocellulose and probed with radiolabeled Tc1. Standard reactions contained Mgcl<sub>2</sub> (lanes 1 to 3 and 5 to 11) or EDTA (lane 4). Products were digested with ScaI in vector DNA (lane 2, 7, 10) or ApaI in Tc1 DNA (lane 3) prior to electrophoresis. Lanes 5, 8 and 11 show reaction products when the substrate is linearized with ScaI prior to in vitro cleavage. Lanes 1 to 5 show reaction products using pRP466 as substrate which carries a complete Tc1 element (see Figure 4). Lanes 6 to 8 use pRP467 as substrate which has a deleted left end of Tc1, whereas lanes 9 to 11 show pRP4678 as substrate, which has the right end of Tc1 deleted. REC and LEC stands for Right and Left End Cleavage, respectively. RH and LH indicate the positions of the Right and Left Half of Tc1. A schematic of ScaI-linearized pRP466 is shown at the bottom of the figure.

**Figure 2.** Mapping of the in vitro cleavage sites at the nucleotide level. A PCR based primer extension was performed on reaction products obtained in the presence of Mgcl<sub>2</sub> (+) or EDTA(-) using pRP466 as donor. A control reaction was performed with pRP466 digested with EcoRV (RV lanes) to demonstrate the addition of one extra nucleotide at the end of the PCR product by Taq polymerase (see Clark 1988). Products were analyzed on a sequencing gel. Sequence reactions (GATC) were loaded as markers. PCR was with primer R2 (right panel) or primer B1GR (left panel). The relevant sequence is indicated with the EcoRV site boxed and the TA target site underlined. The cleavage sites are shown by arrows. Identical results were obtained when the positions of cleavage at the other transposon end was determined.

**Figure 3.** Schematic representation of the genetic transposition assay. The donor plasmid, a pACB104 derivative (Boyd and Sherratt 1995) with a lambda origin of replication, contains a Tc1 element carrying an antibiotic resistance gene. The target plasmid, pRP475, carries a 1,4 kb *hindII gpa-2* fragment and a Col E1 origin of replication (pSP72, Promega). Reaction products were electroporated into a lambda lysogen. *E. coli* strain to counterselect against the donor. Integration events were selected on double antibiotics.

**Figure 4.** Target site selection. Comparison of the distribution of in vitro (black bars) and in vivo (open bars) Tc1 insertions. pRP472 as donor and pRP475 as target were used in standard in vitro transposition reactions using *C. elegans* extract. Every mark on the X-axis represents a TA dinucleotide in the *gpa-2* fragment as described in detail elsewhere (Van Luenen and Plasterk 1994).

**Figure 5.** Purification of Tc1 transposase from *E. coli*. Analysis of transposase purified from inclusion bodies on a 12% SDS-polyacrylamide gel. Lane M: molecular weight markers (indicated in KDa); lane 1: bacterial lysate before induction; lane 2: bacterial lysate after induction; lane 3: purified inclusion bodies; lane 4: purified transposase after refolding.

**Figure 6.** Mutations at the extreme termini of Tc1 affect excision. In vitro reaction products were obtained using *C. elegans* extract in the presence of MgCl<sub>2</sub> (+) or EDTA (-) using as donor pRP480 (wt), pRP481 (TA), pRP482 (CA), pRP483 (GT) or pRP484 (BS), as indicated at the top. Products were separated on a 1% agarose gel, transferred to nitrocellulose and probed with radiolabeled Kan<sup>R</sup>-gene fragment. The donor plasmids contain 28-mers cloned into the *SmaI*-site (wt sequence) and the *HindII*-site (wt or mutant sequence) of pUC19 with the Kan<sup>R</sup>-cassette of pUC4K



in between. TA was mutated to CG, CA to TG and GT to AC, respectively. In the transposase binding site mutation the *Bal*I and *Eco*RV sites are mutated to TCCCA and GGGCCC, respectively (see Vos and Plasterk 1994).

5 **Figure 7.** Model for *Tc*I transposition. A model for non-replicative *Tc*I transposition showing the excised, linear element with a 2 bp 3' staggered overhang. Integration results in a duplication of the TA target site. Repair of the double strand break leads to the generation of  
10 characteristic footprints (see also Van Luenen et al. 1994).

**Figure 8:** *Tc*I-transposase is not toxic for human cells. The cell line 911 was transfected with 2 µg pRc/CMV.*Tc*I<sub>A</sub> or 2 µg pRc/CMV per 5 cm, and monoclonal cell lines were  
15 established from G418 resistant colonies. From each cell line, 50 µg whole cell extract was separated on a 10% PAA gel and subsequently analysed for *Tc*I-transposase. *Tc*I-transposase was detected in the cell lines transfected with pRc/CMV.*Tc*I<sub>A</sub> (lanes 1-5), whereas no *Tc*I-transposase could  
20 be detected in the negative control cell lines transfected with pRc/CMV (lanes 6-8).

**Figure 9:** Southern blot of *in vitro* excision reaction products of pRP466.SV-neo1.PGK-tk2, catalysed by *Tc*I-transposase purified from *E.coli*.. Incubation of the donor  
25 plasmid pRP466.SV-neo1.PGK-tk2 with purified *Tc*I-transposase (lane 1), but not with NEB (lane 2) results in excision of the *Tc*I.SV-neo transposon (lane 1). Thus, the plasmid pRP466.SV-neo1.PGK-tk2 can serve as a *Tc*I.SV-neo transposon donor plasmid.

30

**Table 1.** Transposition frequencies. *In vitro* *Tc*I transposition reactions were carried out with supercoiled (SC) or linear donor plasmids and with protein sources as indicated and the ratios of amp<sup>R</sup>-kan<sup>R</sup> to amp<sup>R</sup> colonies  
35 (\*10<sup>6</sup>) are shown for two independent experiments. No

integration products were recovered when reactions were performed in the presence of EDTA.

**Table 2:** Formation of G418 resistant colonies after co-transfection of pRP466.SV-neo1.PGK-tk2 with pcDNA1/TclA or pcDNA1/amp. The cell line 911 was co-transfected with pRP466.SV-neo1.PGK-tk2 and pcDNA1/TclA or pcDNA1/amp. For a period of 18 days, the transfected cells were put on G418 selection medium. Subsequently, the G418 resistant colonies were stained with methylene blue and counted. Co-transfection of pRP466.SV-neo1.PGK-tk2 with pcDNA1/TclA yielded approximately 40% more G418 resistant colonies than co-transfection with pcDNA1/amp. This indicates that, in addition to random integration, G418 resistant colonies were formed due to jumping of the Tcl-neo transposon into the cellular genome.

**Table 3:** Expression of HSV-tk in G418 resistant cell lines co-transfected with pRP466.sv-neo1.PGK-tk2 with pcDNA1/TclA or pcDNA1/amp. Co-transfection of pRP466.sv-neo1.PGK-tk2 with pcDNA1/TclA yielded more HSV-tk negative (Ganciclovir resistant) colonies than co-transfection with pcDNA1/amp.

Table 1

Donor	source	exp.1	exp.2
pRP490, SC	C. elegans	21	22
pRP490, linear	C. elegans	0.5	1.0
pRP491, SC	C. elegans	3.7	1.6
pRP490, SC	E. coli	3.0	3.2

Table 2

Transfected DNA/5 cm dish	n=	mean number of colonies
2 µg pcDNA1/TclA + 0.1 µg pRP466.SV- neo1.PGK-tk2	3	51
2 µg pcDNA1/amp + 0.1 µg pRP466.SV- neo1.PGK-tk2	3	37
2 µg pcDNA1/TclA + 0.5 µg pRP466.SV- neo1.PGK-tk2	2	206
2 µg pcDNA1/amp + 0.5 µg pRP466.SV- neo1.PGK-tk2	2	144
2 µg pcDNA1/TclA + 2 µg pRP466.SV-neo1.PGK- tk2	2	342
2 µg pcDNA1/amp + 2 µg pRP466.SV-neo1.PGK- tk2	2	251
no DNA	2	0

Table 3

Transfected DNA	n=	% HSV-tk negative
2 µg pcDNA1/Tc1A + 0.1 µg pRP466.SV- neo1.PGK-tk2	16	77
2 µg pcDNA1/Tc1A + 0.5 µg pRP466.SV- neo1.PGK-tk2	19	64
2 µg pcDNA1/amp + 0.1 µg pRP466.SV- neo1.PGK-tk2	19	32
2 µg pcDNA1/amp + 0.5 µg pRP466.SV- neo1.PGK-tk2	18	44

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

(A) NAME: Valerio, Domenico  
(B) STREET: Gerbrandylaan 12  
(C) CITY: Leiden  
(D) STATE: Zuid-Holland  
(E) COUNTRY: the Netherlands  
(F) POSTAL CODE (ZIP): 2314 EZ

(A) NAME: Schouten, Govert Jan  
(B) STREET: Da Costastraat 82  
(C) CITY: Leiden  
(D) STATE: Zuid-Holland  
(E) COUNTRY: the Netherlands  
(F) POSTAL CODE (ZIP): 2321 AR

(A) NAME: Plasterk, Ronald Hans Anton  
(B) STREET: Zwarteweg 5  
(C) CITY: Bussum  
(D) STATE: Noord-Holland  
(E) COUNTRY: the Netherlands  
(F) POSTAL CODE (ZIP): 1405 AA

(A) NAME: van Luenen, Hendricus Gerhard Adrianus Maria  
(B) STREET: Leerdamhof 143  
(C) CITY: Amsterdam  
(D) STATE: Noord-Holland  
(E) COUNTRY: the Netherlands  
(F) POSTAL CODE (ZIP): 1108 BM

(ii) TITLE OF INVENTION: Vectors and methods for providing cells with additional nucleic acid material integrated in the genome of said cells.

(iii) NUMBER OF SEQUENCES: 12

## (iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

## (v) CURRENT APPLICATION DATA:

APPLICATION NUMBER: US 08/909,786

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 44 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CCCCAAGCTT GCCACCATGG TAAAATCTGT TGGGTGTAAA AATC  
44

## (2) INFORMATION FOR SEQ ID NO: 2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GCTCTAGATG CTTAATACTT TGTCGCGTAT CC

32

## (2) INFORMATION FOR SEQ ID NO: 3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 56 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GATCCAAGGA GAGGACGCTG TCTGTCGAAG GTAAGGAACG  
GACGAGAGAA GGGAGA 56

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 52 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

TCTCCCTTCT CGAATCGTAA CCGTTCGTAC GAGAATCGCT GTCCTCTCCT  
TG 52

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

TCAAGTCAAA TGGATGCTTG AG

## (2) INFORMATION FOR SEQ ID NO: 6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GATTTTGTGA ACACTGTGGT GAAG

24

## (2) INFORMATION FOR SEQ ID NO: 7:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GTACGAGAAT CGCTGTCCTC

20

## (2) INFORMATION FOR SEQ ID NO: 8:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO



(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

AGATTTCAC TTATATCATG TTTTATGTTT TGC

33

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

TCCCA

5

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GGGCCC

6

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

CTCTGCTCAT ATGTCACGAC CGGTTTTTCT ATAGGTG

37

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

CACCTATAGA AAAACCGGTC GTGACATATG AGCAGAG

37

CLAIMS

1. A vector for integrating additional nucleic acid material into a cell of a certain genome of a first genus, said vector comprising:
  - two transposase binding sites and
  - 5 a cut site corresponding to each of said transposase binding sites, wherein said transposase binding sites are derived from a transposon found in a second genus;  
wherein each of said transposase binding sites are in close proximity to said corresponding cut site; and
  - 10 wherein the additional nucleic acid material is integrated between said two transposase binding sites of the vector.
2. A vector according to claim 1, whereby the transposase binding sites and cut sites are based on the corresponding
- 15 sites in transposons from the Tc1/mariner superfamily of transposons.
3. A vector according to claim 1 or 2, whereby the transposase binding sites and cut sites are based on Tc1-like transposons.
- 20 4. A vector according to claim 3, comprising at least the terminal 26 basepairs of Tc1 as a transposase binding site and a cut site for the Tc1 transposase.
5. A vector according to anyone of the foregoing claims, further comprising a means for transducing a target cell.
- 25 6. A vector according to anyone of the foregoing claims further comprising a nucleic acid sequence encoding transposase activity, functional for the transposase binding sites and cut sites present in said vector.
7. A vector according to anyone of the foregoing claims,
- 30 whereby the additional nucleic acid material encodes a protein.
8. A vector according to anyone of claims 1-7, whereby the additional nucleic acid material provides a blocking nucleic acid, such as an antisense RNA.

9. A vector according to anyone of the foregoing claims, whereby said vector is derived from a viral vector, preferably an adenoviral, retroviral, or adeno associated viral vector.
- 5 10. A method for providing a target cell with additional nucleic acid material integrated into its genome, comprising transducing said cell with a vector according to anyone of the foregoing claims and providing said target cell with transposase activity functional for the
- 10 transposase binding sites and cut sites present on said vector.
11. A method according to claim 10, whereby the transduction is carried out through infectious particles comprising the vector.
- 15 12. A recombined target cell obtainable by a method according to claim 10 or 11.
13. Use of a functional transposon found in a certain genus in integrating a nucleic acid of interest into the genome of a cell of a different genus.
- 20 14. Use according to claim 13, in a gene therapy regime.
15. Use according to claim 13 for producing transgenic animals.

Fig. 1




Fig. 2




Fig. 3




Fig. 4






Fig. 5




Fig. 6


flank-TACAGT-TBS-Tc1


WT	TA	CA	GT	BS
+	-	+	-	+
-	-	-	+	-
-	+	-	-	-




1 2 3 4 5 6 7 8 9 10

Fig. 7



**Figure 8:**

**Figure 9:**

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/NL 98/00456

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/90 C12N15/55 C12N9/22 C07K14/435 A01K67/027  
A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A01K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, L, X	WO 97 29202 A (HET NL KANKER INSTITUUT ; PLASTERK RONALD HANS ANTON (NL); VOS JAN) 14 August 1997 see the whole document ---	1-15
X	J.C. VOS ET AL.: "Transposase is the only nematode protein required for in vitro transposition of TC1" GENES & DEVELOPMENT, vol. 10, no. 6, 15 March 1996, pages 755-761, XP002088205 CSH LABORATORY PRESS, NEW YORK, US see the whole document --- -/--	1-8, 10, 12, 13

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

16 December 1998

Date of mailing of the international search report

25/01/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Hornig, H

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/NL 98/00456

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	SCHOUTEN G J ET AL: "Transposon Tc1 of the nematode <i>Caenorhabditis elegans</i> jumps in human cells." NUCLEIC ACIDS RESEARCH, (1998 JUN 15) 26 (12) 3013-7. JOURNAL CODE: 08L. ISSN: 0305-1048., XP002088087 see the whole document ----	1-15
A	VOS J C ET AL: "CHARACTERIZATION OF THE CAENORHABDITIS ELEGANS TC1 TRANSPOSASE IN VIVO AND IN VITRO" GENES AND DEVELOPMENT, vol. 7, no. 7A, 1 July 1993, pages 1244-1253, XP000575689 see the whole document ----	1-15
A	VOS J C ET AL: "TC1 TRANSPOSASE OF CAENORHABDITIS ELEGANS IS AN ENDONUCLEASE WITH A BIPARTITE DNA-BINDING DOMAIN" EMBO JOURNAL, (15 DEC 1994) VOL. 13, NO. 24, PP. 6125-6132. ISSN: 0261-4189., XP002088088 cited in the application see the whole document ----	1-15
A	H.G.A.M. VAN LUENEN AND R.H.A. PLASERK: "Target site choice of the related transposable elements Tc1 and Tc3 of <i>Caenorhabditis elegans</i> " NUCLEIC ACIDS RESEARCH, vol. 22, no. 3, 1994, pages 262-269, XP002088089 IRL PRESS LIMITED, OXFORD, ENGLAND cited in the application see the whole document ----	1-15
A	ABAD P ET AL: "Expression and biochemical characterization of the DNA binding activity of TcA, the putative transposase of <i>Caenorhabditis elegans</i> transposable element Tc1." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1993 MAY 14) 192 (3) 1445-52. JOURNAL CODE: 9Y8. ISSN: 0006-291X., XP002088090 see the whole document -----	1-15

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/NL 98/00456

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9729202 A	14-08-1997	AU 1674697 A	28-08-1997